Trial
NCT00515528
Vaccination Plus Ontak in Patients With Metastatic Melanoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Chicago
Collaborators
Eisai Inc.
Condition
Melanoma
Intervention
4-peptide melanoma vaccine
Why stopped
The immune monitoring data failed to demonstrate an improvement in any biologic endpoint with denileukin diftitox.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-01-26